Brain Tumors Ependymoma treatment protocols Study Clinical trial name Phase/type Age AflacST1502: A Phase II Study of Sirolimus in AflacST1502 Combination with Metronomic Chemo-therapy in Children II >12 mo to <30 yr CHOANOME II with Recurrent and/or Refractory Solid and CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02574728 ADVL1823, Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion COG Pediatric Solid Tumors and TRK Fusion Relapsed II <30 yr ADVL1823 Pediatric Acute Leukemias https://clinicaltrials.gov/ct2/show/NCT03834961 APEC1621A: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of COG >12 mo to LOXO-101 (Larotrectinib) in Patients with Tumors II APEC1621AREQ <21 yr Harboring Actionable NTRK Fusions https://clinicaltrials.gov/ct2/show/NCT03213704 APEC1621B: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of COG JNJ-42756493 (Erdafitinib) in Patients with Relapsed >12 mo to II APEC1621BREQ Pediatric Solid Tumors Harboring FGFR1/2/3/4 <21 yr Alterations https://clinicaltrials.gov/ct2/show/NCT03210714 APEC1621C: NCI-COG Pediatric MATCH (Molecular COG Analysis for Therapy Choice) - Phase 2 Subprotocol of >12 mo to II APEC1621CREQ Tazemetostat in Patients with Tumors Harboring <21 yr Alterations in EZH2 or Members of the SWI/SNF Complex https://clinicaltrials.gov/ct2/show/NCT03213665 APEC1621D NCI-COG Pediatric MATCH (Molecular COG Analysis for Therapy Choice) – Phase 2 Subprotocol of II >12 mo to <21 yr APEC1621DREQ LY3023414 in Patients with Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03213678 APEC1621E NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of COG Selumetinib in Patients with Tumors Harboring Activating II >12 mo to <21 yr APEC1621EREQ MAPK Pathway Mutations https://clinicaltrials.gov/ct2/show/NCT03213691 APEC1621F NCI-COG Pediatric MATCH (Molecular COG Analysis for Therapy Choice) – Phase 2 Subprotocol of II >12 mo to <21 yr APEC1621FREQ Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations https://clinicaltrials.gov/ct2/show/NCT03213652 Page 1 of 20 February 28, 2020 CNS APEC1621G NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of COG Vemurafenib in Patients with Tumors Harboring II >12 mo to <21 yr APEC1621GREQ Actionable BRAF V600 Mutations https://clinicaltrials.gov/ct2/show/NCT03220035 APEC1621H NCI-COG Pediatric MATCH (Molecular COG Analysis for Therapy Choice)—Phase 2 Subprotocol of II >12 mo to <21 yr APEC1621HREQ Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes https://clinicaltrials.gov/ct2/show/NCT03233204 APEC1621I NCI-COG Pediatric MATCH (Molecular Analysis COG for Therapy Choice)—Phase 2 Subprotocol of Palbociclib in APEC1621IREQ Patients with Tumors Harboring Activating Alterations in Cell II >12 mo to <21 yr Cycle Genes https://clinicaltrials.gov/ct2/show/NCT03526250 APEC1621J NCI-COG Pediatric MATCH (Molecular Analysis COG for Therapy Choice)—Phase 2 Subprotocol of BVD-523FB APEC1621JREQ (Ulixertinib) in Patients with Tumors Harboring Activating II >12 mo to <21 yr MAPK Pathway Mutations https://clinicaltrials.gov/ct2/show/NCT03698994 A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Ignyta Study of Entrectinib (RXDX-101) in Children and Adolescents >2 to RXDX-101-03 with Recurrent or Refractory Solid Tumors and Primary CNS I/Ib <22 yr Tumors https://clinicaltrials.gov/ct2/show/NCT02650401 LOXO-EXT-17005: A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously LOXO-EXT-17005 I/II >1 mo Treated NTRK Fusion Cancers https://clinicaltrials.gov/ct2/show/NCT03215511 Aflac ST1501, A Phase I Study of Abemaciclib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma and in ≥2 to AflacST1501 Children with Recurrent and Refractory Solid Tumors I <25 yr Including Malignant Brain Tumors https://clinicaltrials.gov/ct2/show/NCT02644460 Aflac ST1601: A Phase I Trial of Temozolomide and >3 to AflacST1601 Everolimus in Children with Recurrent or Refractory Brain I <22 yr Tumors PBTC-045: A Safety and Preliminary Efficacy trial of MK- 3475 (pembrolizumab; anti-PD-1) in Children with Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma >1 to PBTC-045 (DIPG), I <18 yr Non-brainstem High-grade Gliomas (NB-HGG), Ependymoma, Medulloblastoma and Hypermutated Brain Tumors https://clinicaltrials.gov/ct2/show/NCT02359565 PBTC-048: Feasibility Trial of Optune for Children with >5 to PBTC-048 Recurrent or Progressive Supratentorial High-grade Glioma I <21 yr and Ependymoma Page 2 of 20 February 28, 2020 CNS PBTC-050: A Phase I and Surgical Study of Ribociclib and Everolimus (RAD001) in Children with Recurrent or >1 to I PBTC-050 Refractory Malignant Brain Tumors <21 yr https://clinicaltrials.gov/ct2/show/NCT03387020 Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric >1 to I PBTC-051 Subjects with Recurrent/ Refractory Brain Tumors and Newly <21 yr Diagnosed Brain Stem Glioma https://clinicaltrials.gov/ct2/show/NCT03389802 ADVL1615, A Phase 1 Study of Pevonedistat (MLN4924 Part A1: >12 mo to <21 yr COG IND# 136078), a NEDD8 Activating Enzyme (NAE) Inhibitor, I Part A2: ADVL1615 in Combination with Temozolomide and Irinotecan in >6 mo to <12 mo Pediatric Patients with Recurrent or Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03323034 Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Palbociclib (Ibrance®) in Combination with Irinotecan and COG >2 to Temozolomide in Pediatric Patients with Recurrent or I ADVL1921 <21 yr Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03709680 Ependymoma supportive treatment and non-therapeutic protocols Non- AflacPM1702 Aflac Precision Medicine Program (APMP) Study <30 yr therapeutic COG APEC14B1: The Project:Everychild Protocol: Non- APEC14B1 A Registry, Eligibility Screening, Biology and Outcome Study <25 yr therapeutic https://clinicaltrials.gov/ct2/show/NCT02402244 APEC1621SC: NCI-COG Pediatric MATCH (Molecular COG Analysis for Therapy Choice) Screening Protocol NA >12 mo to <21 yr APEC1621SC https://clinicaltrials.gov/ct2/show/NCT03155620 Key Adverse Events after Childhood Cancer (cardiac, stroke, COG Non- secondary malig)/closed to AVN patients as of 11-26-08 <21 yr at dx ALTE03N1 therapeutic https://clinicaltrials.gov/ct2/show/NCT00082745 COG Umbrella Long-Term Follow-Up Protocol Non- All ages ALTE05N1 https://clinicaltrials.gov/ct2/show/NCT00736749 therapeutic Health-related Quality of Life Outcomes during Molecularly QOL Targeted Tx Non- Targeted Therapy for the Treatment of High Risk Pediatric <21 yr Brain Tumors therapeutic Brain Tumors Germ cell tumor treatment protocols ADVL1823, Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid COG Tumors and TRK Fusion Relapsed Pediatric Acute II <30 yr ADVL1823 Leukemias https://clinicaltrials.gov/ct2/show/NCT03834961 Page 3 of 20 February 28, 2020 CNS APEC1621A: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of COG >12 mo to LOXO-101 (Larotrectinib) in Patients with Tumors Harboring II APEC1621AREQ <21 yr Actionable NTRK Fusions https://clinicaltrials.gov/ct2/show/NCT03213704 APEC1621B: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ- COG >12 mo to 42756493 (Erdafitinib) in Patients with Relapsed Pediatric II APEC1621BREQ <21 yr Solid Tumors Harboring FGFR1/2/3/4 Alterations https://clinicaltrials.gov/ct2/show/NCT03210714 APEC1621C: NCI-COG Pediatric MATCH (Molecular COG Analysis for Therapy Choice) - Phase 2 Subprotocol of >12 mo to II APEC1621CREQ Tazemetostat in Patients with Tumors Harboring Alterations <21 yr in EZH2 or Members of the SWI/SNF Complex https://clinicaltrials.gov/ct2/show/NCT03213665 APEC1621D NCI-COG Pediatric MATCH (Molecular COG Analysis for Therapy Choice) – Phase 2 Subprotocol of II >12 mo to <21 yr APEC1621DREQ LY3023414 in Patients with Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03213678 APEC1621E NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Selumetinib in COG Patients with Tumors Harboring Activating MAPK Pathway II >12 mo to <21 yr APEC1621EREQ Mutations https://clinicaltrials.gov/ct2/show/NCT03213691 APEC1621F NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Ensartinib in COG Patients with Tumors Harboring ALK or ROS1 Genomic II >12 mo to <21 yr APEC1621FREQ Alterations https://clinicaltrials.gov/ct2/show/NCT03213652 APEC1621G NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of COG Vemurafenib in Patients with Tumors Harboring Actionable II >12 mo to <21 yr APEC1621GREQ BRAF V600 https://clinicaltrials.gov/ct2/show/NCT03220035 APEC1621H NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of COG Olaparib in Patients with Tumors Harboring Defects in DNA II >12 mo to <21 yr APEC1621HREQ Damage Repair Genes https://clinicaltrials.gov/ct2/show/NCT03233204 APEC1621I NCI-COG Pediatric MATCH (Molecular Analysis COG for Therapy Choice)—Phase 2 Subprotocol of Palbociclib in II >12 mo to <21 yr APEC1621IREQ Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes https://clinicaltrials.gov/ct2/show/NCT03526250 APEC1621J NCI-COG Pediatric MATCH (Molecular Analysis COG for Therapy Choice)—Phase